Awardee OrganizationBETH ISRAEL DEACONESS MEDICAL CENTER
Description
Abstract Text
Nuclear receptor (NR) signaling is essential for normal development as well as normal
metabolic and physiologic function in humans. In addition, NRs are potential targets in
a variety of human diseases. Central to the action of NRs is their ability to recruit the
transcriptional corepressors, nuclear receptor corepresor (NCoR) and silencing
mediator of retinoic acid and thyroid hormone receptors (SMRT), in the absence of
ligand or in the presence of antagonists to target key pathways. In the following
proposal we will use novel mouse models to understand how NCoR and SMRT
specifically interact with target NRs in vivo. In particular we will focus on the thyroid
hormone receptor (TR) and the liver x receptor (LXR) to understand the role of the
corepressors in vivo as we have determined already that NCoR can regulate their
signaling. In the first Aim, we will determine if corepressor specificity exists in vivo by
analyzing the role of both NCoR and SMRT individually and together in context of
thyroid hormone action in the liver. In the second Aim, we will focus on exploring the
role of NCoR in both congenital hypothyroidism and resistance to thyroid hormone.
Both of these human diseases are hypothesized to be due to aberrant corepressor
recruitment, though this has never been tested in vivo. In the third Aim, we will
determine the role of NCoR in LXR-signaling both in the liver and in a variety of other
key target issues. These studies will have direct applicability to the regulation of
cholesterol metabolism in vivo. Interestingly, because LXR and TR intersect in the
regulation of a number of key gene targets in cholesterol metabolism this Aim will also
allow us to determine whether NCoR action is specific to a target NR. The completion of
these three Aims will allow for greater comprehension of how modulation of corepressor
signaling in vivo alters key metabolic pathways. Furthermore this work should lead to
novel insight into the target specificity of individual corepressors and their role in key
disease states that affect human health.
Public Health Relevance Statement
Narrative
The transcriptional corepressors, NCoR and SMRT, have been hypothesized to
play a key role in a variety of human diseases including leukemia, congenital
hypothyroidism, resistance to thyroid hormone (RTH), metabolic inflammation
and hormone-related cancers because of their ability to be recruited to nuclear
receptors. By focusing on the role of these corepressors in their interactions with
the thyroid hormone receptors and the liver x receptor we will gain insight into
the mechanism by which these corepressors function in the whole animal. In
addition, our studies should shed new light on congenital hypothyroidism, RTH
and hypercholesterolemia as our approach will directly test the role of
corepressors in these diseases.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
071723621
UEI
C1CPANL3EWK4
Project Start Date
15-August-2000
Project End Date
31-July-2010
Budget Start Date
01-August-2009
Budget End Date
31-July-2010
Project Funding Information for 2009
Total Funding
$425,000
Direct Costs
$250,000
Indirect Costs
$175,000
Year
Funding IC
FY Total Cost by IC
2009
NIH Office of the Director
$425,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2R56DK056123-10
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R56DK056123-10
Patents
No Patents information available for 2R56DK056123-10
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R56DK056123-10
Clinical Studies
No Clinical Studies information available for 2R56DK056123-10
News and More
Related News Releases
No news release information available for 2R56DK056123-10
History
No Historical information available for 2R56DK056123-10
Similar Projects
No Similar Projects information available for 2R56DK056123-10